Multiple Myeloma

Multiple Myeloma

November, 2022 Treatment Possibilities for R/R Multiple Myeloma After BCMA-Directed CAR T-Cell Therapy

November, 2022 Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

November, 2022 FDA Grants Breakthrough Therapy Designation to Elranatamab for Relapsed/Refractory Multiple Myeloma

November, 2022 Year in Review: Multiple Myeloma

October, 2022 Janssen’s Tecvayli granted FDA approval for multiple myeloma

Overview of Multiple Myeloma

Multiple myeloma is a hematologic (blood) malignancy that forms in a type of white blood cell called a plasma cell. Plasma cells are a type of fully developed B lymphocytes, a group of white blood cells that originate in the bone marrow and play an important role in the immune system. This disease is called “multiple” myeloma because tumors often develop in more than one location in the bone marrow.

In myeloma, one population of normal antibody-producing plasma cells transform into malignant myeloma cells and replicate uncontrollably. Instead of producing healthy germ fighting antibodies, the malignant cells produce abnormal proteins (such as monoclonal M- protein) that crowd out and inhibit the production of normal blood cells and antibodies in the bone marrow.

Symptoms associated with Multiple Myeloma “CRAB” hyperCalcemia, Renal insufficiency, Anemia, Bone lesions: The immune system is negatively affected by the overproduction of one antibody and can no longer effectively target all pathogens. As the plasma cells continue to multiply, damage to organs can occur, specifically the kidneys. Anemia results when the myeloma prevents the bone marrow from producing red blood cells. Osteolytic lesions (soft spots in the bone) by melanoma cells often replace solid healthy bone marrow.

Treatment for Multiple Myeloma
Clinical Trials for Multiple Myeloma

National Cancer Institutes Multiple Myeloma Trial Results Clinical trial search

International Myeloma Foundation Clinical Trial Research Multiple Myeloma Clinical Trials

More Multiple Myeloma Opportunities for Research & Education

Trial Check: service from the Leukemia & Lymphoma Society

MMRF Multiple Myeloma Research Foundation Clinical Trial Search

Additional Educational Resources for Multiple Myeloma

American Cancer Society

American Society of Hematology

Be The Match Bone Marrow or Cord Blood Transplant Resource

E Cancer Education

The Multiple Myeloma Research Consortium

The Leukemia & Lymphoma Society

Signal Genetics’ MyPRS

Recent News for Multiple Myeloma

CAR T-Cell Therapy Holds Promise for Multiple Myeloma
March 12, 2018

NICE consulting again on Celgene’s Revlimid for multiple myeloma
The Pharma Letter
July 31, 2014

Lenalidomide for multiple myeloma
The Pharaceutical Journal
August 1, 2014

Higher carfilzomib dose induced durable response in multiple myeloma
HemOnc Today
July 29, 2104

Major Advances in Multiple Myeloma to be Highlighted at 2014 AACC Annual Meeting Newswire
August 1, 2014

Phase III Study of Daratumumab in Front Line Multiple Myeloma
July 19, 2104

Now Enrolling Patients for Multiple Myeloma Clinical Trials at Manhattan Hematology Oncology Associates.

Read More
Support Groups for Multiple Myeloma

International Myeloma Foundation Support Groups

Cancer Care Support Groups

More Multiple Myeloma Opportunities for Research & Education

Daily Strength Online Message Boards

American Cancer Society Support Groups

Multiple Myeloma Living with Myeloma Support Community

Cancer Support Community: Multiple Myeloma

Caring4Cancer Support Groups

Imerman Angels (to connect directly with another survivor or caregiver through an organization that creates personal, one-on-one connections among patients, survivors, and caregivers)

Fighting Chance NY- free counseling service for cancer patients and caregivers